Clinical Impact of Early Tumour Shrinkage in Metastatic or Unresectable Oesophageal Cancer Treated with Pembrolizumab plus Chemotherapy

CONCLUSION: Our findings suggest that an ETS is a promising on-treatment marker for early prediction of further sensitivity to pembrolizumab plus CF therapy.PMID:38052183 | DOI:10.1159/000535186

Source: Oncology - December 5, 2023 Category: Cancer & Oncology Authors: Takahito Sugase Takashi Kanemura Tomohira Takeoka Norihiro Matsuura Yasunori Masuike Naoki Shinno Hisashi Hara Takeshi Omori Masatoshi Kitakaze Masahiko Kubo Yosuke Mukai Toshinori Sueda Shinichiro Hasegawa Hirofumi Akita Junichi Nishimura Hiroshi Wada Ma Source Type: research